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Abstract.
Background: The translation of evidence on dementia risk factors into clinical advice requires careful evaluation of the
methodology and scope of data from which risk estimates are obtained.
Objective: To evaluate the quantity, quality, and representativeness of evidence, we conducted a review of reviews of risk
factors for Alzheimer’s disease (AD), Vascular dementia (VaD), and Any Dementia.
Methods: PubMed, Cochrane library, and the Global Index Medicus were searched to identify meta-analyses of observational
studies of risk factors for AD, VaD, and Any Dementia. PROSPERO CRD42017053920.
Results: Meta-analysis data were available for 34 risk factors for AD, 26 risk factors for Any Dementia and eight for
VaD. Quality of evidence varied greatly in terms of the number of contributing studies, whether data on midlife exposure
was available, and consistency of measures. The most evidence was available for cardiovascular risk factors. The most
geographically representative evidence (five of six global regions) was available for alcohol, physical activity, diabetes,
high midlife BMI, antihypertensives, and motor function. Evidence from Australia/Oceana or Africa was limited. With the
exception of diabetes, meta-analysis data were unavailable from Latin America/Caribbean. Midlife specific data were only
available for cholesterol and arthritis.
Conclusion: There is a lack of midlife specific data, limited data on VaD, and a lack of geographical representation for
many risk factors for dementia. The quality, quantity, and representativeness of evidence needs to be considered before
recommendations are made about the relevance of risk factors in mid- or late-life or for dementia subtypes.
Keywords: Alzheimer’s disease, cohort studies, meta-analysis, prevention, risk factor, vascular dementia
INTRODUCTION
Dementia prevalence will continue to increase due
to population aging and will cause a significant bur-
den of disease [1], unless the onset of dementia is
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delayed [2]. Older adults commonly have dementia
of mixed pathology that is amenable to modifica-
tion by treatment of vascular risk factors. Therefore,
data on risk factors for dementia is increasingly
used to inform national preventative health policy
as illustrated by the recent publication of evidence
reports [3, 4]. However, the evidence base to sup-
port recommendations for dementia risk reduction
falls short of what is a growing demand by the
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scientific community for reproducibility of methods
and results. The 2017 Lancet Commission report [4]
made recommendations for risk reduction based on
two sources: a United States Government Report pub-
lished in 2010 [5]; and the United Kingdom National
Clinical Practice Guidelines (NICE guidelines) [6],
which provided a narrative review of the literature. It
concluded that childhood education, exercise, main-
taining social engagement, reducing smoking, and
management of hearing loss, depression, diabetes,
and obesity are key risk factors which collectively
have the potential to delay or prevent a third of
dementia cases [4]. The recent United States National
Academies’ Consensus Report focused on system-
atic reviews of interventions, and identified cognitive
training, hyper/hypotension and physical activity as
reducing dementia risk but that evidence for these was
only modest [3]. There has been limited quantitative
evaluation of the volume, quality, and generalizabil-
ity of the body of observational evidence available
for putative risk factors for dementia. Global rec-
ommendations have been based on findings drawn
from narrow geographical regions and with limited
age range. Evaluating the breadth and depth of a
body of evidence allows for clarification of evidence
gaps, areas of bias, and provides a bird’s eye view of
the field [7]. We therefore aimed to conduct a novel
umbrella systematic review of the observational evi-
dence for risk factors for dementia to produce an
overview of the global evidence in the field, focusing
on the types of information required to underpin the
development of clinical practice guidelines [8]. We
evaluate both the quantity of evidence and its rep-
resentativeness, and identify areas of bias resulting
from pooling of results in meta-analyses.
MATERIALS AND METHODS
Search strategy and eligibility criteria
A systematic review of reviews was con-
ducted [9], and pre-registered in PROSPERO
CRD42017053920. PubMed, the Cochrane Library,
and the Global Index Medicus (which cov-
ered LILACS, WPRIM, IMEMR, IMSEAR, WHO
IRIS, AIM, MedCarib) (inception to 8, Septem-
ber 2018) and reference lists of retrieved articles
were also manually searched and content experts
in the field were consulted for other relevant
publications.
The following search strategies were employed:
PubMed/Medline: ((risk OR “protective factors”
[Mesh]) OR precipitating factors[MeSH Terms])
OR ((prevention and control[MeSH Terms]) OR
risk factors[MeSH Terms]) OR etiology[MeSH
Terms]) OR epidemiology[MeSH Terms])) AND
(dementia OR alzheimer’s OR alzheimers OR
alzheimer OR “dementia”[Mesh] OR “cognitive
dysfunction”[Mesh] OR healthy brain OR brain
health)) AND (meta-analysis OR meta-analyses)
AND systematic[sb]); Cochrane Library: #1: MeSH
descriptor: [Dementia] explode all trees; #2: MeSH
descriptor: [Mild Cognitive Impairment] explode all
trees;#3: MeSH descriptor: [Causality] explode all
trees; #4: MeSH descriptor: [Epidemiologic Fac-
tors] explode all trees; #5: #1 or #2; #6: #3 or
#4; #7: #5 and #6 in Other Reviews; Global Index
Medicus: mh:(“Alzheimer Disease” OR “Dementia,
Vascular” OR “Dementia”)) AND (mh:(“Risk Fac-
tors” OR “Causality” OR “Epidemiologic Factors;
PsycINFO:
1 exp Protective Factors/ (4806)
2 expEtiology/ or expRisk Factors/ or expEpidemi-
ology/ (142956)
3 exp PREVENTION/ (55681)
4 cognitive dysfunction.mp. (5918)
5 alzheimer’s disease.mp. or exp Alzheimer’s Dis-
ease/ (55884)
6 exp DEMENTIA/ or DEMENTIA.mp. (90379)
7 risk.mp. (346369)
8 (meta-analysis or meta-analyses).mp. [mp= title,
abstract, headingword, table of contents, key con-
cepts, original title, tests & measures] (30891)
9 1 or 2 or 3 or 7 (438985)
10 4 or 5 or 6 (101538)
11 8 and 9 and 10 (618)
12 limit 11 to “0830 systematic review” (121)
13 limit 12 to yr=“1860 - 2018” (120)
Any systematic review of a risk factor for
Alzheimer’s disease (AD), Vascular dementia (VaD),
or Any Dementia was eligible. Reviews were
excluded if they specified their primary outcome
was early-onset dementia/familial AD. Only reviews
of longitudinal studies were included. If a pooled
estimate contained cross-sectional and longitudinal
data, hazard ratios for longitudinal primary studies
were extracted and risk ratios re-pooled. Reviews
were excluded if the majority of primary studies
obtained dementia diagnoses from medical records
solely, if they included primarily clinical samples,
did not report inclusion and exclusion criteria, did
not conduct meta-analyses, or were not published in
peer-reviewed journals, so as to exclude low quality
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reviews. Non-English publications were translated
with Google Translate.
Data screening and extraction
Citations of all publications returned by the search
strategies were screened for duplicates and remaining
reviews screened in two further stages. At least two
independent reviewers rated each article; inconsisten-
cies in decisions on inclusion were resolved through
discussion and consensus. Abstracts were screened
for relevance and where there was insufficient infor-
mation available for a decision, they were tentatively
included. All remaining publications underwent full-
text review for assessment against inclusion and
exclusion criteria.
Data extracted for potential meta-analysis and nar-
rative review included: risk exposure measured at
midlife (<65 years) or late-life (65+ years); demen-
tia outcome (AD, VaD [10], and Any Dementia
which, potentially included AD, VaD, dementia with
Lewy bodies, frontotemporal dementia/Pick’s dis-
ease, alcohol related dementia, mixed and other
dementias); study design (sample source, number of
participants, observation period), sample character-
istics (country, percentage female, average age of
participants included in the review, age range, average
years of education), risk factor reviewed, number of
studies, measurement of dementia or cognition, unad-
justed and adjusted estimates of association, hazard
ratio (HR), relative risk (RR), beta, p-values with
95% confidence intervals (CI), and I2. From each
article, we extracted the number of individual studies
included in each meta-analysis, and the specific study
details to allow for evaluation of how many studies
were included in multiple meta-analyses, as well as
the continent/region in which the original data were
collected (North America, Europe, Asia/Middle East,
Australia/Oceana, Africa, Latin America).
Quality assessment
The quality of evidence was evaluated at three lev-
els: risk factor, meta-analysis (i.e., per pooled risk
estimate), and publication and was informed by the
literature on factors that affect the quality of evi-
dence as identified by the GRADE initiative [11] and
tailored specifically to dementia epidemiology. For
example, AD pathology accumulates over decades
and the prodromal period may last several years so
that the significance of the length of exposure to a risk
factor must be interpreted taking this into account.
Risk factor evidence quality
‘Body of Evidence Metrics (BEM)’ (Table 1)
were developed based on the premise that a strong
body of evidence for supporting dementia preven-
tion programs across the world would draw from
study populations that represent a wide range of coun-
tries and ethnicities, and include: mid- and late-life
risk factors; information on the relationship of the
risk factor to AD, VaD, and Any Dementia; high
quality systematic reviews of sufficient sample size
and length of follow-up, with consistently defined
exposure and outcome measures. Ideally, the body
of evidence would be based on recent studies, par-
ticularly for a risk factor that may be susceptible to
history and cohort effects.
Quantity and recentness of evidence
1. Quantity of primary studies: The number
of primary studies included per meta-analyses (n)
(Table 1), the total number of unique primary studies
per risk factor (N), and degree of overlap in inclusion
of studies within individual meta-analyses (R= n/N)
(Supplementary Table 1) were recorded.
2. Recency of reviews was calculated as the per-
centage of reviews published within the last five years
(since 2013) for a given risk factor.
Exposure
3. Quality of exposure measure (Table 1): Use of
standard definitions and variability of measures used
for each risk factor and commentary on type of mea-
sure (e.g., categorical, scale). This metric evaluates
variation in the consistency of exposure measures that
are pooled in meta-analyses.
Outcome
4. Outcome measure as clinical diagnosis: the per-
centage of reviews that did or did not use a standard
clinical outcome measure (i.e., Diagnostic and Sta-
tistical Manual, the International Classification of
Diseases, and other widely used classification sys-
tems or Consensus criteria published by groups of
experts).
5. Subtypes of dementia represented (AD, VaD,
Any Dementia).
Population
6. Primary baseline age-group represented per risk
factor (midlife 40–59; late-life 60+; and percentage
of studies in which baseline age is unknown) [4].
7. Range of follow-up (Table 1) and percent-
age long-term follow-up: For each risk factor, the
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Body of Evidence Metrics: Representativeness, quality and quantity of evidence per risk factor
K
.J
.Anstey
et
al./U
m
brella
Review
ofD
em
entia
Risk
F
a
ctors
S169
(Continued)
S170
K
.J
.Anstey
et
al./U
m
brella
Review
ofD
em
entia
Risk
F
a
ctors
Table 1
(Continued)
K
.J
.Anstey
et
al./U
m
brella
Review
ofD
em
entia
Risk
F
a
ctors
S171
( Continued)
S172
K
.J
.Anstey
et
al./U
m
brella
Review
ofD
em
entia
Risk
F
a
ctors
Table 1
(Continued)
Note. SR denotes no. of systematic reviews identified, *the primary ages represented, ‘adj’ denotes age-adjusted (baseline age is not relevant to measures of self-reported educational
attainment), ‘ML’ denotes midlife (baseline age < 65), ‘LL’ denotes late-life (baseline age 65+), ‘?’ denotes unknown. ∧ is the percentage of primary studies where baseline age is not
reported, and “Env.” is environmental. ‘Y’ denotes yes and ‘N’ denotes no. Body of Evidence Metrics. 1‘N’ denotes the quantity of evidence per risk factor; total number of primary
studies for each risk factor 2Indicates standardization and variability of exposures measures within risk factors. 3The percentages of identified reviews which did or did not have
specified clinical diagnosis as an inclusion criteria, or where this was not reported. 4Subtypes of dementia represented: AD, VaD, any. 5Ages groups represented, primary age group,
and % of primary studies where age group is not reported. 6Geographical regions represented.
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number of primary studies with lengths of follow-up
in the following categories: < 5 years, 5–9.9 years,
10–19.9 years, and 20+ years, or unknown length
of follow-up was identified. The percentage of pri-
mary studies with long follow-up periods (i.e., ten
or more years follow-up) was reported. Length of
follow-up is important because dementia has a long
prodromal period, so shorter studies have increased
risk of reverse causality.
8. Geographical regions: global generalizability
(see Table 1 and see Fig. 2), number of regions repre-
sented across all estimates in risk factor/ total of six
possible regions × 100. Risk of bias when generaliz-
ing findings in relation to a risk factor is increased
if the majority of evidence is derived from a single
geographical area.
Meta-analysis quality
A representativeness statistic was calculated using
number of primary studies pooled per risk estimate
divided by the total number of primary studies per risk
factor. Lower scores indicate that the meta-analysis
is reporting a smaller proportion of the available evi-
dence base for that risk factor. It is expected that older
meta-analyses would have a lower representativeness
statistic and more recently published meta-analyses
have a higher statistic (detailed summary on indi-
vidual meta-analyses and pooled risk estimates in
Supplementary Table 1). A validated measure of evi-
dence overlap for meta-analyses termed Corrected
Covered Area (CCA %) [12] was estimated for
each risk factor and is reported in Supplementary
Table 5, and associated interpretive descriptors are
represented in Fig. 3.
Publication quality
Risk of bias of included reviews were rated using
the AMSTAR scale [13] (Supplementary Table 3).
AMSTAR provides rating of domains of potential
bias and is not intended to be used as a total score.
Studies included are listed in Supplementary Table 4.
Data synthesis and analysis
Data were collated and synthesized with a sum-
mary provided according to risk factor by age, i.e.,
exposure for midlife only, late-life only, or stud-
ies combining exposure in both. Results were also
reported separately for AD, Any Dementia, and
VaD where data were available. Summary effect
sizes and 95% CI with fixed effects and random
effects models for each meta-analysis were used
to determine significance and size of study effects;
between-study heterogeneity was assessed with I2
(the proportion of between-study variance to the
sum of within- and between-study variances), which
ranges from 0% to 100%. Where meta-analyses con-
tained non-prospective data or where I2 was not
reported, individual study HRs and 95% CI were
extracted. Summary estimates and I2 statistics were
re-calculated using Meta-Analysis software version
3.0 and Stats Direct 3.1.
RESULTS
Of the 825 articles identified, 809 were screened
and 203 reviewed at full-text of which 113 were
deemed ineligible (reasons for exclusion provided
in Supplementary Table 2). We identified 91 arti-
cles reporting meta-analyses that met criteria for
our review (see Fig. 1), and these contained 271
pooled estimates for 36 risk factors for AD (Table 1),
VaD, and Any Dementia (study characteristics are
reported in Supplementary Table 1). Risk factors
were classified as demographic, lifestyle (includ-
ing diet and nutrient factors which were grouped
together), medical, pharmacological, or environmen-
tal. BEMs are reported in Table 1 and Fig. 2 (for
AD). The number of unique primary studies included
in systematic reviews for a given risk factor ranged
from two (e.g., carotid atherosclerosis, peripheral
artery disease, antacids) to 90 (e.g., diets) (Fig. 2 and
Supplementary Table 1) with more than 40 studies
included for smoking, depression, and diabetes, and
20–39 studies included for education, alcohol, phys-
ical activity, body mass index (BMI), cholesterol,
Fig. 1. Study identification and selection flow chart.
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Fig. 2. World maps showing distribution of evidence on risk factors for Alzheimer’s disease and Any Dementia.
hyper/hypotension, antihypertensives, and statins.
CCA estimates indicated that degree of overlap
between reviewed studies was highest for physi-
cal activity, diabetes, traumatic brain injury (TBI),
cancer, stroke, statins, anti-inflammatories, hormone
replacement therapy (HRT), and pesticides (Fig. 3).
Risk factors with a high number of primary papers
and frequency of reviews, but with slight to moder-
ate CCA included: education, alcohol, diet, BMI, and
atrial fibrillation. Fewer than five studies were iden-
tified for bilingualism, stress, carotid atherosclerosis,
inflammatory markers, metabolic syndrome, periph-
eral artery disease, renal disease, serum uric acid,
antacids, benzodiazepines, and pesticides. For around
half of the risk factors, all the reviews included had
been published in the last six years, in contrast to
the risk factors of smoking, alcohol, and homocys-
teine where fewer than 40% of the reviews had been
published within the past six years.
We found that individual meta-analyses did pro-
vide new and different information from each other.
On average they reported a minority 27% of the total
studies published per risk factor. This highlights the
importance of considering the evidence per risk fac-
tor as a whole rather than relying on evidence from
specific meta-analysis. In general, AMSTAR rating
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quality was higher for more recent reviews (Sup-
plementary Table 3). The most common area where
studies lost points was lack of a specified “a priori”
research design (e.g., registered protocol) (86% of
reviews), and not providing a list of excluded stud-
ies (80% of reviews). It was assumed that protocols
did not exist if not mentioned. Standard measures
of exposures were lacking for cognitive engagement,
diet, social engagement, stress, hormones, and pesti-
cides, and risk factors varied greatly in the degree
to which component meta-analyses used exposure
measures consistently, e.g., meta-analyses of cogni-
tive engagement included studies with exposure to
high participation in cognitive activities, intellectual
activities, and stimulating activities.
Around one quarter of the meta-analyses used stan-
dard outcome measures (Table 1). Reviews lacking a
requisite clinical diagnosis criterion included demen-
tia outcomes based on non-diagnostic measures like
the Mini-Mental State Exam (MMSE), informant
or self-report of medical history, or another non-
standard cognitive test. Meta-analyses of BMI and
smoking had particularly low proportions (<25%) of
studies with specified clinical diagnostic criteria for
dementia. Some meta-analyses (bilingualism, social
engagement, sleep, anxiety, hearing loss, inflam-
matory markers, motor function, serum uric acid,
antacids, and insulin sensitizers) did not report use
of any standard outcomes or were unclear in their
reporting. AD was the most common dementia sub-
type to be investigated as an outcome. Only 8/39
risk factors were evaluated for VaD. Social engage-
ment, anxiety, hearing loss, and motor function
have not been reviewed as risk factors for either
VaD or AD.
Where age-group was reported, the evidence on
bilingualism, cognitive and social engagement, atrial
fibrillation, anxiety, cancer, carotid atherosclero-
sis, depression, hormones, inflammatory markers,
metabolic syndrome, motor function, peripheral
artery disease, renal disease, serum uric acid, stroke,
HRT, and pesticides is drawn from studies that com-
menced in later life only (Table 1). In this case, it
is unclear whether these factors, when occurring in
midlife, are associated with dementia risk. Age group
was not reported for antacids, benzodiazepines, and
insulin sensitizers. The evidence for all other risk
factors included studies of middle-aged as well as
older adults, though there were specific gaps in age
coverage for dementia sub-types; for example, most
meta-analyses of risk factors for VaD only included
exposures measured in late-life.
The greatest proportion of evidence from long
follow-up (10 + years) was for motor function (80%
of studies), insulin sensitizers (75% of studies), and
bilingualism (75% of studies) (range 3–23 years but
missing data precluded estimate of proportion with
long follow-up). Additional risk factors with at least
a third of the evidence derived from long follow-
up included insulin sensitizers (75%), hearing-loss
(70%), sleep (60%), BMI (57%), antacids and serum
uric acid (50%), cancer (46%), diabetes (42%),
cholesterol (41%), smoking (40%), education (33%),
and HRT (30%) (see Fig. 3). In addition, 51% of risk
factors identified had reviews with incomplete report-
ing of study follow-up duration with, on average,
follow-up durations being omitted for 25% of com-
ponent studies. Risk factors with the least complete
follow-up information include anti-inflammatories
(87% missing), benzodiazepines (100% missing),
and TBI (81% missing). Risk factors for which
the body of evidence is based only on short term
follow-ups (<10 years) include carotid atherosclero-
sis, metabolic syndrome, peripheral artery disease,
renal disease, serum uric acid, stroke, and pesticides.
Those with the longest follow-up periods (40+ years)
include smoking and BMI.
The most geographically representative evidence
(covering five of six regions) was available for
alcohol, physical activity, diabetes, motor function,
and antihypertensives, followed by diet, smok-
ing, social engagement, anxiety, hormones, and
hyper/hypotension (four of six regions). Figure 2
shows the distribution of data on a map of the world
with the most risk factor data drawn from Northern
Europe.
There was no evidence from Asia/Middle East
on bilingualism, cognitive engagement, stress,
BMI, cancer, carotid atherosclerosis, inflammatory
markers, metabolic syndrome, peripheral artery dis-
ease, antacids, benzodiazepines, anti-inflammatories,
HRT, statins, and pesticides. Meta-analysis evidence
from Australia/Oceana or Africa was relatively lim-
ited, and, with the exception diabetes, evidence from
Latin America/Caribbean was unavailable.
Table 2 lists the 33 risk factors for AD for which
meta-analyses were available, the number of stud-
ies contributing to each pooled risk estimate, the
age of exposure (midlife or late-life), and the num-
ber of reviews contributing to results per risk factor.
Egger’s test was non-significant for most risk fac-
tors and results for heterogeneity were varied both
between meta-analysis of the same risk factor and
between risk factors. Nineteen risk factors had effect
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sizes drawn from more than five studies and had
non-significant tests for bias or low to moderate het-
erogeneity (I2 < 50%).
Significant associations with AD increased risk
were found for clinical depression versus no depres-
sion (RR: 2.04 (1.40, 2.98) [14]), diabetes versus
no diabetes (RR: 1.39 (1.16, 1.66) [15] to 1.57
(1.41, 1.75) [16]), high BMI predominantly in midlife
versus normal BMI (RR: 1.35 (1.19, 1.54) [17]
to 2.04 (1.59, 2.69) [17]), low educational attain-
ment versus high (RR: 1.32 (1.09, 1.59) [18] to
1.78 (1.43, 2.22) [19]), high homocysteine ((RR:1.15
(1.09,1.23) [20] to 2.50 (1.38, 4.56) [21]), smok-
ing (RR:1.12 (1.00, 1.26) [22] to 1.99 (1.33, 2.98)
[23]), depression increase risk per increase in depres-
sive symptom (RR: 1.06 (1.02, 1.10) [14] to 1.65
(1.42, 1.92) [24]), and decreased risk for NSAIDS
(RR: 0.42 (0.26, 0.66) [25] to 0.74 (0.57, 0.97)
[26]), alcohol (any or light/moderate versus absti-
nence) (RR: 0.43 (0.17, 0.69) [20] to 0.72 (0.61,
0.86) [27]), physical activity guidelines/more active
versus inactive/less active (RR: 0.55 (0.36, 0.84)
[28] to 0.80 (0.69, 0.94) [29]), fish (highest versus
lowest) (RR: 0.64 (0.44, 0.92) [30] to 0.93 (0.90,
0.95) [31]), and coffee/caffeine intake versus no caf-
feine (RR: 0.69 (0.47, 0.90) [20] to 0.73 (0.55, 0.97)
[32]). There was a mixed pattern of findings from
meta-analyses of some risk factors, including statins,
inflammatory markers, hyper/hypotension, and TBI.
For the remaining risk factors (including cognitive
activity, vitamin D deficiency, Mediterranean dietary
pattern, stress, sleep, arthritis, carotid atheroscle-
rosis, metabolic syndrome, serum uric acid), there
was only one or a few systematic reviews and
few contributing studies, thus providing insuffi-
cient evidence to draw even tentative conclusions
(Table 2).
Figure 3 visually depicts the body of evidence
metrics for all risk factors for all outcomes. The fig-
ure shows for example that for Bilingualism, data
are recent, drawn from late-life with 10 years of
exposure, based on 4 contributing studies in a sin-
gle review, with most studies missing data on age
of exposure. In comparison, the evidence for physi-
cal activity is drawn from 8 systematic reviews that
include 35 cohort studies and include exposure in
midlife and late life. Data on diabetes is drawn from 8
reviews that include a total of 54 studies, and includes
information on midlife and late-life. Hence the body
of evidence for physical activity and diabetes is far
larger and covers a wider age-range than the evidence
for bilingualism.
Of the 26 risk factors evaluated with Any Demen-
tia as an outcome (Supplementary Table 1), those for
which there was at least one individual meta-analysis
of more than 20 studies were physical activity,
smoking, and depression. Among meta-analyses for
education and atrial fibrillation, the largest number of
studies was 14, for hearing loss, 13, for statins, 12,
and for antioxidants, 11. In meta-analyses of alco-
hol, coffee, fat, fish, vitamin C, D, and E intake,
sleep social engagement, anxiety, BMI, hormones,
TBI, antihypertensives, insulin sensitizers, the largest
number of studies included was 5–10. All other
meta-analyses included at most 2–4 studies. High
educational attainment (highest quartile compared
with reference quartile) (RR: 0.59 (0.41, 0.87) [19])
was associated with a lower risk of Any Demen-
tia. Late-life alcohol consumption (light to moderate
and any, compared with abstinence) (RR: 0.65 (0.54,
0.79) [33] to 0.74 (0.61, 0.91) [27]), statins used in
mid/late-life versus no statins (RR: 0.71 (0.61, 0.96)
[34] to 0.87 (0.82, 0.92) [35]) higher levels of phys-
ical activity (as compared to lower levels) (RR: 0.72
(0.60, 0.86) [28] to 0.86 (0.76, 0.97) [36]), antihy-
pertensives (RR: 0.79 (0.70, 0.89) [37] to 0.86 (0.75,
0.99) [38]) and antioxidants (RR: 0.87 (0.77, 0.98)
[39]) and were associated with reduced risk of Any
Dementia.
Cognitive engagement, Mediterranean diet, fish,
fruit and vegetable, vitamin B and D, and tea drinking
in mid- and late-life were associated with reduced risk
but pooled estimates were derived from fewer stud-
ies (2–5 studies per estimate). Increased risk of Any
Dementia was associated with insomnia (RR: 1.53
(1.07, 2.18) [40]) (5 studies with very high hetero-
geneity), shorter sleep duration as compared to longer
sleep duration (RR: 1.42 (1.15,1.77) [41]), low social
engagement in late-life (RR: 1.41 (1.13, 1.75) [42]
to 1.58 (1.19, 2.09) [42]) obesity (RR: 1.41 (1.20,
1.65) [43] to 1.91 (1.41, 2.62) [44]), underweight
BMI in late-life (RR: 1.36 (1.07, 1.73) [45]), hear-
ing loss (RR: 1.38 (1.23–1.53) [46]), low education
(compared with higher levels of education) (RR: 1.32
(1.09, 1.59) [18] to 1.81 (1.59, 2.06) [19]), and smok-
ing (RR: 1.13 (1.05, 1.22) [22] to 1.43 (1.15, 1.77)
[39]). Coffee/caffeine was not associated with risk of
Any Dementia.
Eight risk factors were evaluated for VaD (Sup-
plementary Table 1), and meta-analyses for which
there were eight or more studies included: diabetes
(RR:1.73 (1.61, 1.85) [47] to 2.49 (2.09, 2.97) [48])
and smoking (RR: 1.25 (1.05, 1.47) [22] to 1.78 (1.28,
2.47) [49]), with a single meta-analyses of six studies
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Table 2
Summary of AD studies by risk factor
Risk Factor Short reference Exposure measure Age group* RR I2 (%) Bias (Egger’s p) n
Demographics
Education Xu 2016 [19] Lowest versus reference
quartile
adj 1.78 (1.43, 2.22) 36.0 absent∧ 9
Xu 2015 [20] Low (<16 y) versus high
(≥16 y)
adj 1.60 (1.32–1.94) 57.0 0.00 14
Caamano-Isorna
2006 [18]
Lower versus highest levels adj 1.32 (1.09, 1.59) absent – 9
Xu 2016 [19] Highest versus reference
quartile
adj 0.44 (0.32, 0.60) 41.5 0.018 10
Lifestyle
Alcohol Drinker versus non-drinkers
Anstey 2009 [27] Drinker versus non-drinkers LL 0.66 (0.47, 0.94) 0.0 ∼ 2
Xu 2015 [20] Ever versus never LL/? 0.43 (0.17, 0.69) 0.0 0.33 3
Anstey 2009 [27] Heavy/excessive versus
non-drinker
LL 0.92 (0.59, 1.45) 0.0 0.22 3
Xu 2015 [20] High versus low/none LL/? 0.96 (0.18, 1.74) 78.8 0.56 3
Xu 2015 [20] Light-moderate
consumption versus
non-drinkers
LL/? 0.61 (0.54, 0.68) 0.0 0.44 5
Anstey 2009 [27] Light to moderate versus
non-drinker
LL 0.72 (0.61, 0.86) 56.4 0.36 6
Cognitive
engagement
Xu 2015 [20] High participation in
cognitive activity
LL/? 0.53 (0.42, 0.63) 90.5 0.00 5
Diet Singh 2014 [50] Adherence to
Mediterranean
diet-highest versus
lowest
LL 0.64 (0.46, 0.89) 0.0 ∼ 2
Xu 2015 [20] Caffeine/coffee drinking ML/? 0.69 (0.47, 0.90) 0.0 0.96 3
Wu 2016 [51] <1 cup coffee per day
versus 1-2 cups
LL 0.71 (0.54, 0.94) 0.0 0.98 3
Kim 2015 [52] Coffee intake-highest
versus lowest
LL 0.71 (0.52, 0.97) 0.0 ∼ 3
Liu 2016 [32] Coffee intake-highest
versus lowest
ML/LL 0.73 (0.55, 0.97) 0.0 0.80 4
Barranco 2007
[53]
Coffee consumption versus
non-consumption
? 0.73 (0.54, 0.99) 0.0 ∼ 2
Xu 2015 [20] Fat, DHA LL/? 0.76 (0.52, 1.11) 68.3 0.04 4
Wu 2015 [30] Fat, DHA/EPA-highest
versus lowest
LL 0.89 (0.74, 1.08) 36.3 0.01 3
Xu 2015 [20] Fat, EPA ? 0.96 (0.75, 1.16) 0.0 0.25 3
Zhang 2016 [31] Fat, DHA-0.1-g/d
increment
ML/LL 0.63 (0.51, 0.76) 94.6 0.10 3
Zhang 2016 [31] Fat, PUFA-8-g/d increment ML/LL 0.96 (0.65, 1.27) 34.6% – 2
Zhang 2016 [31] Fat, EPA-0.1-g/d increment ML/LL 1.04 (0.85, 1.23) 5.1 0.10 2
Wu 2015 [30] Fish intake-highest versus
lowest
LL 0.64 (0.44, 0.92) 59.0 0.10 6
Xu 2015 [20] Fish intake LL/? 0.66 (0.43, 0.90) 64.7% 0.54 6
Zhang 2016 [31] Fish-increment of 1
serving/wk
ML/LL 0.93 (0.90, 0.95) 74.8% 0.174 5
Xu 2015 [20] Folate-high serum folate
levels
LL/? 0.51 (0.29, 0.73) 16.0% 0.29 4
Kim 2015 [52] Tea intake-highest versus
lowest
LL 1.12 (0.83, 1.50) 0.0% ∼ 3
Xu 2015 [20] Vitamin C intake LL/? 0.74 (0.55, 0.93) 0.0% 0.19 6
Xu 2015 [20] Vitamin E intake LL/? 0.73 (0.62, 0.84) 0.0% 0.81 6
Shen 2015 [54] Vitamin D deficiency
(25(OH)D level < 50
nmol/L)
LL/? 1.21 (1.02, 1.41) 0.0% – 2
(Continued)
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Risk Factor Short reference Exposure measure Age group* RR I2 (%) Bias (Egger’s p) n
Physical activity Santos-Lozano
2016 [55]
Physically active (according
to international PA
guidelines:>150
min/week of MVPA)
versus inactive
LL 0.60 (0.51, 0.71) 5.6% 0.34 5
Xu 2015 [20] High participation in
leisure-time PA
LL/? 0.65 (0.46, 0.84) 81.0% 0.09 10
Santos-Lozano
2016 [55]
Higher versus lower PA ML/LL 0.65 (0.55, 0.75) 39.3% 0.83 9
Daviglus 2011
[56]
Higher versus lower PA ? 0.72 (0.53, 0.98) – – 9
Xu 2017 [29] Higher versus lower PA ML/LL 0.80 (0.69, 0.94) 0.0% ∼ 8
Hamer 2009 [28] Highest versus lowest PA ML/LL 0.55 (0.36, 0.84) 79.5% <0.01 6
Beckett 2015 [57] Highest versus lowest PA ML 0.61 (0.52, 0.73) 0.0% 0.02 9
Xu 2017 [29] Highest versus lowest PA ML/LL 0.74 (0.58, 0.94) 46.3% ∼ 8
Sleep Bubu 2016 [58] All sleep
problems/disorders listed
in International
Classification of Sleep
Disorders versus none
ML/LL 1.47 (1.28, 1.69) 66.9% 0.79 6
Smoking Zhong 2015 [22] Current versus never LL 1.40 (1.13, 1.73) 66.8% <0.01 12
Anstey 2007 [49] Current versus former LL/? 1.70 (1.25, 2.31) 0.0% 0.70 4
Anstey 2007 [49] Current versus never LL/? 1.79 (1.43, 2.23) 0.0% 0.89 4
Almeida 2002
[23]
Current versus
never/non-smokers
? 1.99 (1.33, 2.98) 56.5% ∼ 7
Peters 2008 [59] Current versus
never/non-smokers
ML/LL/? 1.59 (1.15, 2.20) 69.9% 0.19 8
Zhong 2015 [22] Ever versus never LL 1.12 (1.00, 1.26) 55.9% <0.01 23
Almeida 2002
[23]
Ever versus never ? 1.10 (0.94, 1.29) 93.5% 0.53 7
Zhong 2015 [22] Former versus never LL 1.04 (0.96, 1.13) 2.8% <0.01 13
Xu 2015 [20] Former versus never 1.00 (0.92, 1.08) 0.0% 0.27 9
Peters 2008 [59] Former versus never ? 0.99 (0.81, 1.23) 46.8% 0.79 8
Medical
Arthritis Xu 2015 [20] History of arthritis
(self-report)
LL/? 0.63 (0.42, 0.84) 0.0% 0.83 2
Atrial fibrillation Kalantarian 2013
[60]
Yes versus no (ECG,
medical history, ICD-9,
unclear)
LL 1.47 (0.92, 2.34) 68.2% ∼ 3
Xu 2015 [20] Yes versus no (medical
records, self-report
health questionnaire)
LL 1.29 (0.97, 1.60) 60.6% 0.94 3
BMI Anstey 2011 [17] Change (increase)
continuous measures of
BMI
LL 0.72 (0.62, 0.84) 71.5% ∼ 2
Xu 2015 [20] High BMI (>28/30) in
midlife versus normal
ML/LL/? 1.61 (1.11, 2.12) 69.2% 0.11 6
Xu 2015 [20] High BMI
(>25–30/abdominal
obesity/BMI increase) in
late-life
LL/? 0.80 (0.64, 0.97) 72.9% 0.95 12
Anstey 2011 [17] Obese versus normal ML/LL 2.04 (1.59, 2.69) 82.8% ∼ 3
Loef 2013 [44] Obese versus normal ML/LL 1.98 (1.24, 3.14) – – 4
Meng 2014 [61] Obese versus normal ML 1.88 (1.32, 2.69) 59.1% 0.55 5
Beydoun 2008
[45]
Obese versus normal ML/LL 1.80 (1.00, 3.29) – <0.01 4
Anstey 2011 [17] Obese versus not Obese LL 1.46 (0.97, 2.21) 42.3% ∼ 2
Anstey 2011 [17] Overweight versus normal ML/LL 1.35 (1.19, 1.54) 92.0% ∼ 3
Loef 2013 [44] Overweight versus normal ML/LL 1.44 (0.96, 2.15) – – 4
Anstey 2011 [17] Underweight versus normal ML/LL 1.96 (1.32, 2.92) 69.1% ∼ 3
(Continued)
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(Continued)
Risk Factor Short reference Exposure measure Age group* RR I2 (%) Bias (Egger’s p) n
Cancer Ma 2014 [62] History of cancer versus
none (ICD code
diagnosis)
LL 0.63 (0.56, 0.72) 0.0% 0.28 5
Xu 2015 [20] Yes versus no
(Questionnaire/self-
report, ASL-Mi1 tumor
registry)
LL/? 0.65 (0.57, 0.73) 6.7% 0.81 6
Carotid
atherosclerosis
Xu 2015 [20] Yes versus no (carotid
medina wall thickness)
1.65 (1.03, 2.26) 31.1% ∼ 2
Cholesterol Anstey 2017 [63] High cholesterol (>6.5
mmol/l) versus
non-high-midlife
ML 2.14 (1.33, 3.44) 12.9% ∼ 3
Meng 2014 [61] High cholesterol (>6.5
mmol/l) versus non-high
ML 1.72 (1.32, 2.24) 8.5% possible∧ 4
Xu 2015 [20] Elevated serum total
cholesterol level
ML/LL/? 1.07 (0.89, 1.28) 59.9% 0.02 16
Daviglus 2011
[56]
Highest versus lowest
quartile
? 0.85 (0.65, 1.12) – ∼ 3
Anstey 2017 [63] Highest versus lowest
quartile-Total
cholesterol, late-life
LL 0.93 (0.69, 1.26) 50.5% 0.28 4
Anstey 2017 [63] Low HDL-C LL 0.78 (0.54, 1.13) 65.4% ∼ 3
Anstey 2008 [17] Second versus lowest
quartile-total cholesterol
LL 0.85 (0.67, 1.10) 40.1% ∼ 3
Depression Cherbuin 2015
[14]
Categorical clinical
thresholds (>20/21
CES-D or equivalent)
LL 2.04 (1.40, 2.98) 54.9% possible∧ 10
Diniz 2013 [24] Continuous (mostly CES-D
& variants)
? 1.65 (1.42, 1.92) 2.0% absent∧ 17
Xu 2015 [20] Continuous (self-reporting,
CES-D, HAM,
Questionnaire, DSM-IV,
Diagnosis, CAMDEX,
Neuropsychiatric
interview, SCL-90)
LL/? 1.08 (1.04, 1.13) 40.3% 0.00 24
Cherbuin 2015
[14]
Continuous symptomology
measures-CES-D, HAM,
GDS, SCL-90, the NEO
LL 1.06 (1.02, 1.10) 62.1% possible∧ 10
Diabetes Zhang 2017 [64] Any diabetes (Type I or II) ? 1.53 (1.42, 1.63) 18.5% absent∧ 17
Meng 2014 [61] Any diabetes (Type I or II) ML/LL 1.40 (1.25, 1.57) 10.6% – 4
Vagelatos 2013
[16]
Type II diabetes, self-report
and blood sampling
ML/LL 1.57 (1.41, 1.75) 38.7% 0.22 15
Gudala 2013 [65] Type II diabetes
(self-reported, registry-
based/antidiabetics
use)
ML/LL 1.56 (1.41, 1.73) 9.8% 0.93 20
Cheng 2012 [48] Type II diabetes (according
to standard criteria)
ML/LL 1.54 (1.40, 1.70) 71.7% <0.01 18
Lu 2009 [15] Type II diabetes (medical
history, laboratory test,
antidiabetic medications)
LL 1.39 (1.16, 1.66) 0.0% <0.01 8
Xu 2015 [20] Type II diabetes
(self-report, family
report)
ML/LL 1.33 (1.14, 1.52) 70.4% 0.06 22
Vagelatos 2013
[16]
Type II diabetes, self-report
and blood sampling
ML/LL 1.57 (1.41, 1.75) 38.7% 0.22 15
Homocysteine Van Dam 2009
[21]
Hyperhomocysteinema LL 2.50 (1.38, 4.56) 81.6% ∼ 3
Xu 2015 [20] High total homocysteine
levels
ML/LL/? 1.15 (1.09, 1.23) 45.0% 0.00 8
(Continued)
S180 K.J. Anstey et al. / Umbrella Review of Dementia Risk Factors
Table 2
(Continued)
Risk Factor Short reference Exposure measure Age group* RR I2 (%) Bias (Egger’s p) n
Hormones Wang 2016 [66] High versus normal levels
of thyrotropin
LL 1.70 (1.18, 2.45) 42.2% 0.75 2
Wang 2016 [66] Low versus normal levels of
thyrotropin
LL 1.69 (1.31, 2.19) 38.0% 0.74 4
Lv 2016 [67] Low plasma testosterone (in
elderly men)
? 1.48 (1.12, 1.96) 47.2% 0.15 7
Wang 2016 [66] Per SD increment in
thyrotropin levels
LL 0.89 (0.78, 1.01) 31.3% 0.01 6
Hyper/Hypotension Meng 2014 [61] All combined-high SBP,
DBP, hypertension
ML/LL 1.31 (1.01, 1.70) 45.7% – 5
Meng 2014 [61] High DBP ML/LL 2.38 (1.34, 4.23) 0.0% – 3
Meng 2014 [61] High SBP ML/LL 1.77 (0.93, 3.37) 0.0% – 3
Xu 2015 [20] Higher SBP ? 1.02 (0.92, 1.13) 68.7% <0.01 28
Meng 2014 [61] Hypertension versus none ML/LL 1.10 (0.88, 1.37) 48.6% – 2
Guan 2011 [65] Hypertension versus none ML/LL 1.01 (0.87, 1.18) 37.2% – 9
Xu 2015 [20] Lower DBP LL/? 1.14 (0.89, 1.39) 60.0% <0.01 6
Power 2011 [68] Per 10 mmHg DBP ML 0.93 (0.84, 1.04) 12.4% 0.85 4
Power 2011 [68] Per 10 mmHg DBP LL 0.94 (0.85, 1.04) 14.0% 0.45 5
Power 2011 [68] Per 10 mmHg increment
SBP
ML 0.95 (0.90, 1.00) 69.4% ∼ 4
Power 2011 [68] Per 10 mmHg increment
SBP
LL 0.95 (0.91, 1.00) 0.0% 0.54 5
Sharp 2011 [69] History of/current
hypertension
? 1.59 (1.29, 1.95) 37.4% <0.01 6
Power 2011 [68] History of hypertension ML/LL 0.98 (0.80, 1.19) 41.8% 0.69 12
Inflammatory
markers
Koyama 2013 [70] C-reactive protein LL 1.36 (1.13, 1.63) 40.3% ∼ 3
Koyama 2013 [70] Interleukin-6 LL 1.15 (0.84, 1.59) 0.0% ∼ 4
Metabolic
syndrome
Xu 2015 [20] NCEP ATP III criteria LL/? 0.71 (0.49, 0.93) 36.5% 0.30 4
Peripheral artery
disease
Xu 2015 [20] Ankle to Brachial
Index < 0.9–11
LL/? 1.68 (0.97, 2.38) 0.0% 0.51 2
Renal Disease Xu 2015 [20] eGFR (MDRD), I/SCr,
questionnaire
LL/? 1.13 (0.68, 1.59) 0.0% 0.67 3
Serum uric acid Du 2016 [71] Serum uric acid levels ? 0.66 (0.52, 0.85) 6.0% low risk∧ 3
Stroke Xu 2015 [20] Self-reported history of
stroke
LL/? 0.97 (0.71, 1.24) 40.9% 0.03 –9
Zhou 2015 [72] Stroke diagnosis based on
the International
Classification of Diseases
LL 1.59 (1.25, 2.02) 0.0% ∼ 5
TBI Xu 2015 [20] Head trauma with/without
loss of consciousness
LL/? 1.18 (0.89, 1.47) 7.5% 0.16 6
Li 2017 [73] Prior TBI LL/? 1.24 (1.04, 1.49) 26.8 0.32 8
Perry 2016 [74] Prior TBI ? 0.95 (0.58, 1.54) 51.4% 0.83 7
Pharmacological
Antacids Virk 2015 [75] Aluminum containing
antacids
? 0.70 (0.30, 1.80) 0.0% ns 2
Virk 2015 [75] Antacid ? 0.83 (0.39, 1.78) 0.0% ns 2
Antihypertensives Xu 2015 [20] Anti-hypertensives LL/? 0.71 (0.59, 0.83) 52.7% 0.36 5
Xu 2017 [38] Anti-hypertensives LL 0.83 (0.64, 1.07) 40.5% possible∧ 6
Chang-Quan 2011
[76]
Anti-hypertensives ML/LL/? 0.92 (0.79, 1.08) 0.0% 0.66 5
Guan 2011 [77] Anti-hypertensives ML/LL 0.92 (0.79, 1.08) 0.0% 0.66 5
Anti-
inflammatories
Wang 2015 [78] Aspirin LL/? 0.74 (0.57, 0.97) 67.9% – 8
Etminan 2003 [79] Aspirin ML/LL 0.85 (0.71, 1.03) 80.5% 0.90 5
Wang 2015 [78] Non-aspirin NSAIDs LL/? 0.61 (0.43, 0.88) 68.6% 0.04 7
Szekely 2004 [25] NSAIDs-exposure for 2 or
more years
ML/LL/? 0.42 (0.26, 0.66) 0.0% ∼ 3
Xu 2015 [20] NSAIDs LL/? 0.67 (0.44, 0.90) 65.8% <0.01 9
(Continued)
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Szekely 2004 [25] NSAIDs-lifetime exposure ML/LL/? 0.74 (0.62, 0.89) – absent∧ 4
Wang 2015 [78] All NSAIDS LL/? 0.69 (0.56, 0.86) 79.7% 0.10 12
Etminan 2003 [79] All NSAIDs ML/LL 0.84 (0.54, 1.05) 62.3% 0.95 6
HRT LeBlanc 2001 [80] Any use versus never use LL 0.50 (0.30, 0.80) 0.0% ∼ 2
Xu 2015 [20] Any use versus never use LL/? 0.61 (0.46, 0.76) 38.1 <0.01 4
O’Brien 2014 [81] Any use versus never use ? 0.69 (0.48, 1.00) 31.4% 0.78 8
Insulin sensitizers Ye 2016 [82] Insulin-sensitizers versus
non-insulin sensitizers
? 0.90 (0.55, 1.45) – unobvious∧ 2
Statins Zhou 2007 [83] Any use versus non-user ? 0.90 (0.65, 1.25) 0.0% ∼ 3
Xu 2015 [20] Current use versus never
use
LL/? 0.59 (0.45, 0.73) 26.4% 0.29 5
Xu 2015 [20] Former versus never use ? 1.28 (0.69, 3.24) 74.6% ∼ 2
Xu 2015 [20] Longer use versus never use ? 0.24 (0.07, 0.70) 0.0% ∼ 2
Wong 2013 [84] Users versus non-users ? 0.70 (0.60, 0.80) 18.2% minimal∧
Richardson 2013
[35]
Users versus non-users ML/LL/? 0.79 (0.63, 0.99) 91.6% 0.38 10
Environmental
Pesticides Yan 2016 [85] Pesticide exposure LL/? 1.37 (1.08, 1.75) 0.0% 0.66 3
Xu 2015 [20] Occupational exposure to
pesticides
LL/? 1.26 (0.93, 1.59) 5.4% 0.78 3
Note.*the primary age represented per pooled effect (RR) is denoted by bold text. ‘adj’ denotes age-adjusted (baseline age is not relevant
to measures of self-reported educational attainment), ‘ML’ denotes midlife (baseline age < 65), ‘LL late-life (baseline age 65+) and ‘?’
unknown. ‘RR’ denotes risk ratio, which is the pooled effect size. ‘–’ denotes not reported. ‘∼’ indicates there were too few primary studies
to calculate Egger’s p. ∧bias as indicated by visual inspection of funnel plot. Egger’s values are as reported in primary reviews, but not a
recommended measure of bias when for n< 10. ‘n’ is the number of primary studies included in the meta-analysis for each RR.
identified for hypo/hypertension. Late-life smoking
and overweight/obese BMI in mid- and late-life were
consistently associated with increased risk of VaD.
Reduced risk was associated with light to moderate
alcohol consumption (compared to abstinence) and
physical activity. All other meta-analyses included
2–4 primary studies.
Overall heterogeneity of studies within reviews
was variable and notably high for the one
meta-analysis of cognitive engagement and AD
(I2 = 90.5%) and for the range of meta-analyses for
diet.
DISCUSSION
Increased risk for either or all of AD, VaD, or
Any Dementia is associated with low education,
diabetes, smoking, depression, midlife obesity, high
homocysteine, hypertension (VaD only), atrial fibril-
lation (Any Dementia only), and social engagement
(Any Dementia only). The data for social engage-
ment were limited to late-life and included varied
measures. We also found that reduced risk was
consistently associated with physical activity, fish
consumption, light alcohol consumption, antihyper-
tensives (Any Dementia only), and statin use (AD
and Any Dementia). Hearing loss was associated
with increased risk of Any Dementia but there has
been no review of hearing loss in relation to AD or
VaD [4], and relatively limited evidence is available
for cognitive engagement, dietary pattern, and spe-
cific nutrients as protective factors. Note this reflects
the limited evidence available for these risk fac-
tors currently and it is not a statement about their
putative effect.
The gaps in the evidence base on risk factors for
dementia are remarkable. By far the majority of data
are reported for AD. Data are limited on vascular
risk factors for VaD, with only one meta-analysis on
physical activity, and no meta-analysis on statins in
relation to VaD. A significant number of risk fac-
tors have been established primarily in studies of
older adults (alcohol, atrial fibrillation, social engage-
ment, cognitive engagement, depression, hormones,
metabolic syndrome, peripheral artery disease, renal
disease, serum uric acid, stroke, pesticides) thus omit-
ting midlife exposure (which leads to gaps in long
term follow-up). Major gaps occur in data from non-
European and non-North-American continents. For
example, data on BMI are drawn from fewer than 40%
of world regions and there are no meta-analysis data
in this review on BMI as a risk factor for dementia
from Asian samples. Evidence for stress, inflamma-
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Fig. 3. Body of evidence metrics for all risk factors.
tory markers, and peripheral artery disease is drawn
from one region. Sleep and social engagement as
risk factors have not been reviewed in relation to
dementia subtypes. Although the AMSTAR scores
were generally high, we identified a lack of com-
monly used exposure measures for some risk factors
(e.g., cognitive engagement). The AMSTAR rating
does not capture some important methodological
features that contribute to quality and bias in rela-
tion to this specific field and we needed to develop
new metrics to capture important causes of bias
in this literature.
The strengths of this review include its compre-
hensiveness and the evaluation of study quality and
quantity. Reviews had clinical diagnoses of demen-
tia and exclusion of individuals with dementia at
baseline. This review has not considered mediating
factors or whether risk factors are proxies for other
variables. For example, it is possible that the risk of
dementia associated with BMI is mediated by cul-
tural or genetic factors such as Western-style diet
and that BMI is a proxy for other socio-cultural fac-
tors. It is also possible that genotype interacts with
risk exposure such that subgroups of the population
may benefit more from risk reducing strategies or
be harmed more by specific exposures (e.g., alco-
hol drinking). In addition, reverse causality was
not evaluated and is a particular concern for risk
factors identified only in late-life data such as cog-
nitive engagement and AD. Meta-analyses do not
include all published studies so the review may
not include all the available data on every risk
factor reviewed. Another potential source of bias
is that selected meta-analyses may over-represent
older primary studies which may not be relevant
to current cohorts.
Understanding the risk and protective factors
influencing cognitive aging and dementia requires
a life-course approach and studies with long-term
follow-ups. Much work is needed to identify critical
time points for exposure, and to establish whether
a common set of risk factors applies in different
countries, at different ages of exposure, and for
different dementia subtypes. Given the overlap of
risk factors for dementia with other chronic disease
areas, it is economical to adopt global chronic dis-
ease strategies for key risk factors such as smoking,
insufficient physical activity, diabetes, depression,
and hypertension. However, as evidence grows we
expect more nuanced approaches to dementia risk
reduction will be needed for specific populations and
age-groups. The evidence reported in this review may
be used to inform guideline development and iden-
tify research gaps, and areas where policy is based on
strong versus weak evidence. This review provides
the best evidence currently available representative-
ness, quality and quantity of evidence on risk factors
for dementia.
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